Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: Early experience of use in clinical practice

Internal Medicine Journal

Volumn 35, Issue 10, 2005, Pages 580-585

  Gearry, Richard B ^a,b   Barclay, M L ^a,b   Roberts, R L ^a   Harraway, J ^c   Zhang, M ^b,c   Pike, L S ^c   George, P M ^c   Florkowski, C M ^c  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b CHRISTCHURCH HOSPITAL   (New Zealand)

^c CANTERBURY HEALTH LABORATORIES   (New Zealand)

Author keywords

6 mercaptopurine; Azathioprine; Pharmacogenetics; Thiopurine metabolites; Thiopurine methyltransferase

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; AZATHIOPRINE; MERCAPTOPURINE; METHYLMERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL PRACTICE; DOSE CALCULATION; ENTERITIS; ENZYME ACTIVITY; ERYTHROCYTE; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; LABORATORY DIAGNOSIS; LEUKOPENIA; MAJOR CLINICAL STUDY; METABOLISM; NEUTROPENIA; NEW ZEALAND; PRIORITY JOURNAL; RISK;

6-MERCAPTOPURINE; AZATHIOPRINE; BIOLOGICAL MARKERS; ERYTHROCYTES; GENOTYPE; GUANINE NUCLEOTIDES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; METHYLTRANSFERASES; THIONUCLEOTIDES;

EID: 27644565720     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2005.00904.x     Document Type: Article

References (30)

1. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A Meta-anatysis. Ann Intern Med 1995; 123: 132-42.
2. Lamers CB, Griffioen G, van Hogezand RA, Veenendaal RA. Azathioprine: an update on clinical efficacy and safety in inflammatory bowel disease. Scand J Gastroenterol Suppl 1999; 230: 111-15.
3. George J, Present DH, Pou R, Bodian C, Rubin PH. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol 1996; 91: 1711-14.
4. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2000; CD000545.
5. Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000; CD000545.
6. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50: 485-9.
7. Bouhnik Y, Lemann M, Mary JY, Scemama G, Tai R, Matuchansky C et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996; 347: 215-19.
8. Gardiner SJ, Begg EJ, Barclay ML, Kirkpatrick CM. Genetic polymorphism and outcomes with azathioprine and 6-mercaptopurine. Adverse Drug React Toxicol Rev 2000; 19: 293-312.
9. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992; 43: 329-39.
10. Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Theoret Y et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705-13.
11. Cuffari C, Theoret Y, Latour S, Seidman G. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996; 39: 401-6.
12. Elion GB. Nobel Lecture. The purine path to chemotherapy. Biosci Rep 1989; 9: 509-29.
13. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32: 651-62.
14. Collie-Duguid ES, Pritchard SC, Powrie RH, Sludden J, Collier DA, Li T et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 1999; 9: 37-42.
15. Gearry RB, Barclay ML, Burt MJ, Collett JA, Chapman BA, Roberts RL et al. Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18: 395-400.
16. Maddocks JL, Lennard L, Amess J, Amos R, Thomas RM. Azathioprine and severe bone marrow depression. Lancet 1986; 1: 156.
17. Walmsley TA, Florkowski CM, George PM, Pike LS. Thiopurine methyltransferase activity and azathioprine. N Z Med J 2002; 115: 302.
18. Weinshilboum RM, Raymond FA, Pazmino PA. Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clin Chim Acta 1978; 85: 323-33.
19. Lennard L, Lilleyman JS. Individualizing therapy with 6-mercaptopurine and 6-thioguanine related to the thiopurine methyltransferase genetic polymorphism. Ther Drug Monit 1996; 18: 328-34.
20. Roberts RL, Barclay ML, Gearry RB, Kennedy MA. A multiplexed allele-specific polymerase chain reaction assay for the detection of common thiopurine S-methyltransferase (TPMT) mutations. Clin Chim Acta 2004; 341: 49-53.
21. Reuther LO, Sonne J, Larsen N, Dahlerup JF, Thomsen OO, Schmiegelow K. Thiopurine methyltransferase genotype distribution in patients with Crohn's disease. Aliment Pharmacol Ther 2003; 17: 65-8.
22. Evans WE, Hon YY, Bomgaars L, Coutre S, Holdsworth M, Janco R et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001; 19: 2293-301.
23. Lowry PW, Franklin CL, Weaver AL, Pike MG, Mays DC, Tremaine WJ et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001; 49: 665-70.
24. Derijks LJ, Gilissen LP, Engels LG, Bos LP, Bus PJ, Lohman JJ et al. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. Ther Drug Monit 2004; 26: 311-18.
25. Hindorf U, Lyrenas E, Nilsson A, Schmiegelow K. Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease. Scand J Gastroenterol 2004; 39: 1105-12.
26. Goldenberg BA, Rawsthorne P, Bernstein CN. The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease. Am J Gastroenterol 2004; 99: 1744-8.
27. Wright S, Sanders DS, Lobo AJ, Lennard L. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut 2004; 53: 1123-8.
28. Herrlinger KR, Fellermann K, Fischer C, Kreisel W, Deibert P, Schoelmerich J et al. Thioguanine-nucleotides do not predict efficacy of tioguanine in Crohn's disease. Aliment Pharmacol Ther 2004; 19: 1269-76.
29. Thomas CW, Lowry PW, Franklin CL, Weaver AL, Myhre GM, Mays DC et al. Erythrocyte mean corpuscular Volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Inflamm Bowel Dis 2003; 9: 237-45.
30. Dubinsky MC, Yang H, Hassard PV, Seidman EG, Kam LY, Abreu MT et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002; 122: 904-15.